Australia's Lumos Diagnostics rises on product expansion by US care network

Lumos Diagnostics Holdings

Mon 01:27

** Shares of Australia's Lumos Diagnostics LDX.AX rise as much as 31.6% to A$0.079, their biggest intraday pct gain since mid-July 2025
** Shares hit their highest level since October 27
** The diagnostics company says US-based WellStreet Urgent Care will expand adoption of its FebriDx respiratory infection test to an additional 97 locations across the United States
** Company says rollout will increase the number of WellStreet sites using FebriDx to 141 from 44
** Adds expects rollout to expand to all WellStreet locations by December 31
** About 5.5 million shares change hands, nearly 3.7x the 30-day average
** YTD, stock down 74.7%, including session's moves 


 (Reporting by Subhalakshmi Dey in Bengaluru)
 ((Subhalakshmi.Dey@thomsonreuters.com;))